1,638.00
+37.00
(2.31%)
May 24 - Close
TYO
data delayed by 20 mins -
Disclaimer
Currency in JPY
| Range | 1,501.00 - 1,726.00 |
| 52 week | 186.00 - 2,540.00 |
| Open | 1,681.00 |
| Vol / Avg. | 991,300.00/2.96M |
| Mkt cap | 56.26B |
| P/E | - |
| Div/yield | - |
| EPS | -33.57 |
| Shares | 34.34M |
| Beta | - |
| Inst. own | - |
Events
Aug 12, 2013
Q1 2014 Shin Nippon Biomedical Laboratories Ltd Earnings Release
Jun 27, 2013
Shin Nippon Biomedical Laboratories Ltd Annual Shareholder Meeting (Japanese)
May 15, 2013
Full Year 2013 Shin Nippon Biomedical Laboratories Ltd Earnings Presentation (Japanese)
May 14, 2013
Full Year 2013 Shin Nippon Biomedical Laboratories Ltd Earnings Release
|
|
Key stats and ratios
| Q1 (Mar '13) | 2013 | |
| Net profit margin | -6.37% | -6.78% |
| Operating margin | -9.89% | -8.47% |
| EBITD margin | - | -0.31% |
| Return on average assets | -4.19% | -3.48% |
| Return on average equity | -50.30% | -34.31% |
| Employees | 1,691 | - |
| Carbon Disclosure Rating | - | - |
Address
12F, St.Luke's Tower, 8-1, Akashi-cho
CHUO-KU, TKY 104-0044
Japan
+81-3-55655001 (Phone)
+81-3-55656160 (Fax)
CHUO-KU, TKY 104-0044
Japan
+81-3-55655001 (Phone)
+81-3-55656160 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2012, the Company had 25 subsidiaries and one associated company. On January 21, 2013, it established a Kagoshima-based subsidiary.
Officers and directors
| Ryoichi Nagata | President, Chief Senior Director of Sales, Chief Director of Global Business Development, Chairman of Subsidiaries, Representative Director | |
| Shinji Nitanda | Executive Officer, Chief Director of Finance and Accounting | |
| Hisao Nakajima | President of Subsidiary, Director | |
| Takeshi Yamakawa | Chief Executive Officer of Subsidiary, Director | |
| Toshihiko Seki | Vice President, Deputy Chief Senior Director of Sales, Representative Director | |
| Koichiro Fukuzaki | Senior Managing Director, CEO of Subsidiary | |
| Ken Takanashi | Senior Managing Director, Deputy Chief Director of Global Business Development | |
| Hidenobu Sameshima | Managing Director, Director of Safety Research Institute | |
| Kazumi Uchi | Executive Director | |
| Satoshi Matsumoto | Chief Director of General Affairs and Human Resources, Director |
